Anbio Biotechnology (NNNN)

• Market cap: $1.23B
• 1 day: -1.37%
• 5 days: -19.28%
• 1 month: 2.83%
• 3 months: -35.87%
• 6 months: 210.88%
• Year to date: 385.44%
• 1 year: 385.44%
• 5 years: 385.44%
• 10 years: 385.44%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Employees: 27